In total, 11 consecutive pediatric patients with Griscelli syndrome (GS) type 2, who received allogeneic hematopoietic SCT (aHSCT) at our center between 1993 and 2007, were reviewed. The median age at transplantation was 8.2 months (range, 4-36.3 months) and the median time from diagnosis to transplantation was 3.7 months (range, 1.4-19.5 months). Seven patients developed an accelerated phase and were treated with chemotherapy before transplantation. At the time of transplantation, all patients were in clinical remission. The source of grafts was matched-related marrows in eight patients and partially mismatched unrelated cords in three patients. All patients were engrafted at a median time of 15 days (range, 12-36 days). Grade I-II acute GVHD and venoocclusive disease occurred in three and one patient, respectively. A total of 10 patients are now alive and disease free at a median of 4.8 years post-HSCT. The post transplant course was complicated by CMV infection in four patients. One patient died in remission from septic shock, 6 months after transplantation. Chimerism studies at the last contact are available for nine patients: six patients have complete donor chimerism and three have stable mixed chimerism. Early aHSCT from matchedrelated donors or unrelated cord blood for children with GS is feasible.
Introduction
Griscelli syndrome (GS) is a very rare autosomal recessive disease, characterized by skin hypopigmentation and silvery-gray hair. In most patients, hair microscopy characteristically reveals large clumps of pigment distributed irregularly along the hair shaft. Unlike ChediakHigashi syndrome, granulocytes in GS do not show giant granules.
1,2 GS is classified into three types on the basis of genetic and molecular features. GS type 1 is caused by a mutation in the myosin Va (MYO5A) gene located on chromosome 15q21, which regulates organelle transport in both melanocytes and neuronal cells. 3, 4 The outcome is guarded as it depends on the severity of neurological manifestations. GS type 3 is caused by mutation in the gene located on chromosome 2q37.3. The affected patients need no active intervention. 5 GS type 2 (partial albinism with immunodeficiency) is caused by mutation in the Rab27a (RAB27A) gene located on chromosome 15q21. 6, 7 In the first few years of life, hemophagocytic lymphohistiocytosis (HLH) in these patients can be triggered by infections. 8 The prognosis is very poor unless early allogeneic hematopioetic SCT (aHSCT) is carried out, preferably before the development of the accelerated phase. To date, few cases of aHSCT in patients with GS have been reported. Table 1 . The median age at diagnosis was 6.8 (range, 0-17.2) months. History of consanguineous parents and history of siblings with GS were observed in nine and seven patients, respectively. The median age at transplant was 8.2 months (range, 4-36.3 months) and median time from diagnosis to transplant was 3.7 months (range, 1.4-19.5 months). The diagnosis of GS was based on the presence of characteristic findings, pigmentary dilution of the skin and hair, the presence of large clumps of pigment in hair shafts and an accumulation of melanosomes in melanocytes. Seven patients had life-threatening accelerated phases (HLH) and four patients were sent to transplantation early on, before the development of HLH, based on previous histories of siblings with GS who had died in accelerated phases. Thus, the diagnosis of type 2 of the disorder was ascertained for all cases. The genetic studies were performed retrospectively on preserved genetic materials of six patients in whom the diagnosis of GS type 2 was confirmed ( Table 1) .
9-14

Materials and methods
Patients
Conditioning regimen
Pre-transplant conditioning regimens included i.v. BU at 4 mg/kg daily in four divided doses on days À10 to À7 (total dose 16 mg/kg), i.v. CY at 50 mg/kg daily on days À5 to À2 (total dose 200 mg/kg) and i.v. VP-16 at 300 mg/m 2 daily on days À5 to À3 (total dose 900 mg/m 2 ) in nine patients, and the same conditioning regimen without VP-16 (BU/CY) in two patients. Four patients, including cord blood recipients, also received rabbit anti-thymocyte globulins (ATG-Fresenius) at 10 mg/kg daily on days À5 to À2 (total dose 40 mg/kg). The grafts were unmanipulated marrows from HLA-identical siblings in eight patients and partially mismatched unrelated cord in three patients, as shown in Table 2 .
Supportive care
All patients were cared for in protective isolation in single rooms with high efficiency particulate air filters. Fever during the neutropenic phase was treated with broad- . CMV-negative patients were transfused with CMV-negative blood products, and all blood products were irradiated. All patients received i.v. Igs every 2 weeks at a dose of 500 mg/kg from day À4 until day þ 90, as well as acyclovir (45 mg/kg per day) from day À3 to day þ 28. CMV was monitored by weekly PCR tests and preemptive treatment was the strategy followed in the unit. Pneumocystis pneumonia prophylaxis continued for 12 months post-HSCT. Table 2 ). The CsA was administered i.v. at a dose of 6 mg/kg per day in two divided doses starting from the day before stem cell infusion until patients were able to tolerate oral CYA. The dose of CYA was titrated to maintain plasma levels between 150 and 200 mg/l. MTX dosage was 10 mg/m 2 i.v. on days þ 1, þ 3 and þ 6. The recipients of the unrelated cord blood units received methylprednisolone (1 mg/kg) i.v. from days þ 5 till þ 20 and tapered over 2 weeks.
GVHD prophylaxis
This consisted of MTX and CsA in eight patients. For the three patients who received cord progenitor stem cells, GVHD prophylaxis was with CsA and methylprednisolone (
Definitions
The criteria for HLH diagnosis were those defined by the Histiocyte Society. 15, 16 The CNS involvement was defined as development of neurological signs and/or symptoms, abnormal cerebrospinal fluid (pleocytosis and/or elevated protein) and neuroradiological findings. 17 The day of stem cell infusion was defined as day 0. CR was defined as complete disappearance of clinical/biological manifestations. Day of engraftment was defined as the first of three consecutive days in which the peripheral ANC was 40.5 Â 10 9 /l. Acute GVHD was graded as 0-IV according to the criteria of Glucksberg et al. 18 Chronic GVHD was defined as none, limited or extensive according to the standard criteria. 19 Death from any cause was considered as an event.
Statistical analysis
The data is analyzed by using the software package SAS version 9.2. (Statistical Analysis System, SAS Institute, Cary, NC, USA). Kaplan-Meier tables and curves are used to calculate the OS.
Results
The median dose of CD34 þ cells was 10. ) per kg of recipient body weight among cord blood recipients (Table 3 ). All patients engrafted well with a median time to engraftment of 15 days (range, 12-36 days) for neutrophils and 28 days (range, 13-57 days) for plts. Two patients developed grade I acute cutaneous GVHD and one developed grade II acute cutaneous GVHD. Two of these patients were recipients of 1-Ag mismatched, unrelated cord blood. No patients have developed chronic GVHD. Self-limited veno-occlusive disease (VOD) was observed in one patient. CMV infections developed in four patients and were resolved with specific therapy.
All patients but one remained as long-term survivors at a median follow-up of 57.6 months (range, 19-156 months) (Figure 1 ). One patient, in remission, succumbed to septic shock 6 months after transplantation. Of the seven patients who had initial CNS involvement, three continued to exhibit mild developmental delay and one had severe developmental delay and speech abnormalities. Chimerism studies at the last contact are available for nine patients: six patients have complete donor chimerism and three have stable mixed chimerism. All three cord blood transplant recipients have complete donor chimerism with normal blood cell counts as shown in Table 4 . Patients with mixed chimerism continue to be disease free. All survivors are infection free and exhibit reasonable immune function (Table 4) . 
Discussion
Type 2 GS patients suffer immunodeficiency and HLH during early childhood. The only curative modality for these patients is aHSCT. Owing to high fatality rates from infections, early disease recurrence and the potential severity of early onset CNS disease, aHSCT should be performed as early as possible. The best results of HSCT have been reported in patients with inactive disease. Thus, transplantation is recommended as soon as remission is achieved. [20] [21] [22] [23] [24] [25] We report the outcomes of aHSCT in 11 patients with type 2 GS. Our data show that aHSCT for patients with GS from either HLA-matched sibling donors or unrelated cord blood is a potentially effective treatment for long-term disease control.
To date, this is the largest cohort of GS patients who have undergone transplantation at a single center. Only a few cases of successful aHSCT have been described previously.
9-14 Schmid et al. 26 recently reported their experience with aHSCT for 10 patients with type 2 GS. At a medium follow-up of 3.4 years, the OS was 70%. Three patients died within the first 4 months post transplantation. HLH recurrence was observed after the second transplant for one patient with a graft failure. Acute GVHD and VOD were observed in seven and five patients, respectively. Interestingly, EBV-post-transplant lymphoproliferative disease was observed in two patients. The outcome was more favorable and the rate of GVHD was lower in our study than in the Schmid et al. study. This result could be explained by the genetically identical transplant and the pre-transplant remission status of the disease in the majority of patients in our study. Patients with familial HLH, including GS, were reported to be at a high risk for VOD post transplant; consequently, the prophylactic use of defibrotide was tried in these patients with encouraging results. 27 In contrast, VOD was not a concern in our patients. Each of our patients had normal liver function before transplantation. Our results and the results of Schmid et al. show that CNS involvement before HSCT is common in these patients (63 and 70%, respectively). Because a considerable number of patients continued to suffer major neurological deficits after HSCT, transplanting these patients before the occurrence of HLH could be a better option. Our results are consistent with previous reports, 28 which show that a low level of donor cell engraftment is sufficient to prevent disease recurrence in patients with GS.
In summary, aHSCT in patients with GS is potentially curative with long-term, disease-free survival. A low level of immune reconstitution by donor cells in GS is sufficient to prevent disease recurrence after transplantation. Unrelated cord blood transplantation in children with GS is feasible in the absence of a compatible-related donor.
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